181 related articles for article (PubMed ID: 19342453)
61. Effects of somatostatin-14 and the receptor-specific somatostatin analogs on chromogranin A and alpha-subunit (alpha-SU) release from "clinically nonfunctioning" pituitary adenoma cells incubated in vitro.
Pawlikowski M; Lawnicka H; Pisarek H; Kunert-Radek J; Radek M; Culler MD
J Physiol Pharmacol; 2007 Mar; 58(1):179-88. PubMed ID: 17440235
[TBL] [Abstract][Full Text] [Related]
62. Mutation of somatostatin receptor type 5 in an acromegalic patient resistant to somatostatin analog treatment.
Ballarè E; Persani L; Lania AG; Filopanti M; Giammona E; Corbetta S; Mantovani S; Arosio M; Beck-Peccoz P; Faglia G; Spada A
J Clin Endocrinol Metab; 2001 Aug; 86(8):3809-14. PubMed ID: 11502816
[TBL] [Abstract][Full Text] [Related]
63. Characterization of cloned somatostatin receptors SSTR4 and SSTR5.
Raynor K; O'Carroll AM; Kong H; Yasuda K; Mahan LC; Bell GI; Reisine T
Mol Pharmacol; 1993 Aug; 44(2):385-92. PubMed ID: 8102785
[TBL] [Abstract][Full Text] [Related]
64. Drug design at peptide receptors: somatostatin receptor ligands.
Hannon JP; Nunn C; Stolz B; Bruns C; Weckbecker G; Lewis I; Troxler T; Hurth K; Hoyer D
J Mol Neurosci; 2002; 18(1-2):15-27. PubMed ID: 11931345
[TBL] [Abstract][Full Text] [Related]
65. BIM-23A760 influences key functional endpoints in pituitary adenomas and normal pituitaries: molecular mechanisms underlying the differential response in adenomas.
Ibáñez-Costa A; López-Sánchez LM; Gahete MD; Rivero-Cortés E; Vázquez-Borrego MC; Gálvez MA; de la Riva A; Venegas-Moreno E; Jiménez-Reina L; Moreno-Carazo A; Tinahones FJ; Maraver-Selfa S; Japón MA; García-Arnés JA; Soto-Moreno A; Webb SM; Kineman RD; Culler MD; Castaño JP; Luque RM
Sci Rep; 2017 Feb; 7():42002. PubMed ID: 28181484
[TBL] [Abstract][Full Text] [Related]
66. Novel long-acting somatostatin analog with endocrine selectivity: potent suppression of growth hormone but not of insulin.
Afargan M; Janson ET; Gelerman G; Rosenfeld R; Ziv O; Karpov O; Wolf A; Bracha M; Shohat D; Liapakis G; Gilon C; Hoffman A; Stephensky D; Oberg K
Endocrinology; 2001 Jan; 142(1):477-86. PubMed ID: 11145612
[TBL] [Abstract][Full Text] [Related]
67. Discovery of iodinated somatostatin analogues selective for hsst2 and hsst5 with excellent inhibition of growth hormone and prolactin release from rat pituitary cells.
Moore SB; van der Hoek J; de Capua A; van Koetsveld PM; Hofland LJ; Lamberts SW; Goodman M
J Med Chem; 2005 Oct; 48(21):6643-52. PubMed ID: 16220980
[TBL] [Abstract][Full Text] [Related]
68. Filamin A is required for somatostatin receptor type 5 expression and pasireotide-mediated signaling in pituitary corticotroph tumor cells.
Treppiedi D; Di Muro G; Mangili F; Catalano R; Giardino E; Barbieri AM; Locatelli M; Arosio M; Spada A; Peverelli E; Mantovani G
Mol Cell Endocrinol; 2021 Mar; 524():111159. PubMed ID: 33428965
[TBL] [Abstract][Full Text] [Related]
69. Somatostatin receptors 2 and 5 are the major somatostatin receptors in insulinomas: an in vivo and in vitro study.
Bertherat J; Tenenbaum F; Perlemoine K; Videau C; Alberini JL; Richard B; Dousset B; Bertagna X; Epelbaum J
J Clin Endocrinol Metab; 2003 Nov; 88(11):5353-60. PubMed ID: 14602773
[TBL] [Abstract][Full Text] [Related]
70. Characterisation of human recombinant somatostatin receptors. 1. Radioligand binding studies.
Siehler S; Seuwen K; Hoyer D
Naunyn Schmiedebergs Arch Pharmacol; 1999 Nov; 360(5):488-99. PubMed ID: 10598788
[TBL] [Abstract][Full Text] [Related]
71. Role of the intracellular domains of the human FSH receptor in G(alphaS) protein coupling and receptor expression.
Ulloa-Aguirre A; Uribe A; Zariñán T; Bustos-Jaimes I; Pérez-Solis MA; Dias JA
Mol Cell Endocrinol; 2007 Jan; 260-262():153-62. PubMed ID: 17045734
[TBL] [Abstract][Full Text] [Related]
72. Octreotide promotes apoptosis in human somatotroph tumor cells by activating somatostatin receptor type 2.
Ferrante E; Pellegrini C; Bondioni S; Peverelli E; Locatelli M; Gelmini P; Luciani P; Peri A; Mantovani G; Bosari S; Beck-Peccoz P; Spada A; Lania A
Endocr Relat Cancer; 2006 Sep; 13(3):955-62. PubMed ID: 16954443
[TBL] [Abstract][Full Text] [Related]
73. Stimulation of adenosine 3',5'-monophosphate production by growth hormone-releasing factor and its inhibition by somatostatin in anterior pituitary cells in vitro.
Bilezikjian LM; Vale WW
Endocrinology; 1983 Nov; 113(5):1726-31. PubMed ID: 6194979
[TBL] [Abstract][Full Text] [Related]
74. Intracerebroventricular injection of somatostatin sst5 receptor agonist inhibits gastric acid secretion in rats.
Martínez V; Coy DH; Lloyd KC; Taché Y
Eur J Pharmacol; 1996 Jan; 296(2):153-60. PubMed ID: 8838451
[TBL] [Abstract][Full Text] [Related]
75. Agonist properties of putative small-molecule somatostatin sst2 receptor-selective antagonists.
Nunn C; Langenegger D; Hurth K; Schmidt K; Fehlmann D; Hoyer D
Eur J Pharmacol; 2003 Apr; 465(3):211-8. PubMed ID: 12681432
[TBL] [Abstract][Full Text] [Related]
76. Pertussis toxin blocks both cyclic AMP-mediated and cyclic AMP-independent actions of somatostatin. Evidence for coupling of Ni to decreases in intracellular free calcium.
Koch BD; Dorflinger LJ; Schonbrunn A
J Biol Chem; 1985 Oct; 260(24):13138-45. PubMed ID: 2865257
[TBL] [Abstract][Full Text] [Related]
77. Fine-tuning somatostatin receptor signalling by agonist-selective phosphorylation and dephosphorylation: IUPHAR Review 5.
Schulz S; Lehmann A; Kliewer A; Nagel F
Br J Pharmacol; 2014 Apr; 171(7):1591-9. PubMed ID: 24328848
[TBL] [Abstract][Full Text] [Related]
78. Porcine sst1 can physically interact with other somatostatin receptors, and its expression is regulated by metabolic/inflammatory sensors.
Gahete MD; Durán-Prado M; Delgado-Niebla E; Garrido JJ; Rhodes SJ; García-Navarro S; Gracia-Navarro F; Malagón MM; Luque RM; Castaño JP
Am J Physiol Endocrinol Metab; 2014 Mar; 306(5):E483-93. PubMed ID: 24368669
[TBL] [Abstract][Full Text] [Related]
79. Arginine residue 155 in the second intracellular loop plays a critical role in rat melanin-concentrating hormone receptor 1 activation.
Saito Y; Tetsuka M; Saito S; Imai K; Yoshikawa A; Doi H; Maruyama K
Endocrinology; 2005 Aug; 146(8):3452-62. PubMed ID: 15890773
[TBL] [Abstract][Full Text] [Related]
80. SOM230: a novel somatostatin peptidomimetic with broad somatotropin release inhibiting factor (SRIF) receptor binding and a unique antisecretory profile.
Bruns C; Lewis I; Briner U; Meno-Tetang G; Weckbecker G
Eur J Endocrinol; 2002 May; 146(5):707-16. PubMed ID: 11980628
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
